Hillsdale Investment Management’s Pacira BioSciences PCRX Stock Holding History

Hillsdale Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.2M	Buy	362,700 +31,400	+9%	+$742K	0.21%	124
2026 Q1	$7.49M	Buy	331,300 +23,100	+7%	+$513K	0.2%	105
2025 Q4	$7.98M	Buy	+308,200	New	+$7.33M	0.22%	90
2024 Q4	–	Sell	-229,200	Closed	-$3.45M	–	655
2024 Q3	$3.45M	Buy	229,200 +134,100	+141%	+$2.29M	0.27%	153
2024 Q2	$2.72M	Sell	95,100 -50,300	-35%	-$1.43M	0.21%	168
2024 Q1	$4.25M	Buy	145,400 +11,400	+9%	+$350K	0.34%	105
2023 Q4	$4.52M	Buy	+134,000	New	+$3.92M	0.37%	84
2019 Q4	–	Sell	-18,200	Closed	-$693K	–	644
2019 Q3	$693K	Hold	18,200	–	–	0.06%	280
2019 Q2	$792K	Buy	18,200 +3,400	+23%	+$144K	0.08%	238
2019 Q1	$563K	Buy	14,800 +4,200	+40%	+$164K	0.05%	269
2018 Q4	$456K	Buy	+10,600	New	+$495K	0.05%	256

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hillsdale Investment Management's PCRX Position: Q2 2026 in Review

Hillsdale Investment Management increased its Pacira BioSciences (PCRX) stake by 9.5% in Q2 2026, buying an estimated $742K and bringing the position to 362,700 shares worth $9.2M. The position accounts for 0.21% of the portfolio, ranked #124.

Hillsdale Investment Management first reported a position in PCRX in Q4 2018 and has held it in 11 quarters since. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Hillsdale Investment Management held 362,700 shares of Pacira BioSciences worth $9.2M as of Q2 2026.
Hillsdale Investment Management bought 31,400 Pacira BioSciences shares in Q2 2026, an estimated $742K.
Pacira BioSciences made up 0.21% of Hillsdale Investment Management's portfolio in Q2 2026, its #124 holding.
Hillsdale Investment Management first reported a position in Pacira BioSciences in Q4 2018 and has held it in 11 quarters since.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.